Oral / Subcutaneous · GLP-1 agonist
ASC30
4 trials in this molecule. Source: ClinicalTrials.gov, as of July 1, 2026.
Trials
4
Active
2
Recruiting
0
Completed
2
Sites
13
Countries
1
Endpoints
16
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Development
Where the program stands
Trials by phase
Phase 1
1
Phase 1/2
1
Phase 2
2
Trials by status
Active, not recruiting
2
Completed
2
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Weight & body composition
7
Safety / tolerability / PK
7
Glycemic / diabetes
2
Most-measured metrics
Top 20 metrics across this asset's endpoints
Trials
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
4 of 4
| Asset / Population | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT07321678A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | ASC30 Type 2 diabetes | BMI ≥23 | Ph 2 | Active, not recruiting | 8 | Aug 2026 | — | |
| NCT07002905A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities | ASC30 Obesity / overweight | — | Ph 2 | Completed | 6 | Dec 2025 | — | |
| NCT06680440A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity | ASC30 Obesity / overweight | — | Ph 1 | Completed | 1 | Apr 2025 | — | |
| NCT06679959A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ASC30 Injection in Participants With Obesity | ASC30 Obesity / overweight | — | Ph 1/2 | Active, not recruiting | 1 | Apr 2026 | — |